Elanco Animal Health awarded derivative securities to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen at $24.50 per share on September 4, 2026. The award, classified under transaction code A, represented about 5.4% of his resulting derivative-securities holding, giving investors a precise view of the disclosed executive transaction.

Key Highlights

  • The transaction was recorded on September 4, 2026 under transaction code A.
  • Robert M. VanHimbergen is Elanco Animal Health’s executive vice president and chief financial officer.
  • Elanco awarded derivative securities to CFO Robert M. VanHimbergen at $24.50 per share.

Elanco Animal Health Inc (NYSE: ELAN) awarded derivative securities to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen at $24.50 per share. The transaction represented about 5.4% of his resulting derivative-securities holding. The recipient is identified as an executive officer of Elanco Animal Health.

$24.50 Derivative Award Recorded

VanHimbergen serves as Elanco Animal Health’s executive vice president and chief financial officer. The transaction occurred on September 4, 2026, under transaction code A, a classification used for an award or grant. Elanco’s securities involved were derivatives, and the stated price was $24.50 per share. The reported holding measure is based on the position after the transaction. The transaction details identify the recipient by name and executive title.

Award Classification Separates Transaction Type

Transaction code A identifies an award or grant rather than an open-market purchase, the relevant distinction for investors reviewing the executive transaction. The percentage measures the awarded transaction against that post-transaction derivative position, while the $24.50 figure remains the per-share amount attached to the instruments. That distinction keeps the disclosed activity separate from a market purchase when investors assess executive ownership changes.